XML 140 R91.htm IDEA: XBRL DOCUMENT v2.4.0.6
Equity Method Investments (Narrative) (Detail) (USD $)
In Millions, except Per Share data, unless otherwise specified
12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Dec. 31, 2012
Janssen AI [Member]
Dec. 31, 2011
Janssen AI [Member]
Dec. 31, 2010
Janssen AI [Member]
Dec. 31, 2009
Janssen AI [Member]
Jan. 31, 2013
Janssen AI [Member]
Subsequent Event [Member]
Dec. 31, 2012
Johnson & Johnson [Member]
Sep. 30, 2009
Johnson & Johnson [Member]
May 31, 2011
Proteostasis [Member]
Dec. 31, 2012
Proteostasis [Member]
Dec. 31, 2011
Proteostasis [Member]
Dec. 31, 2012
Elan Corp Plc share of losses of Jansen Ai [Member]
Dec. 31, 2011
Elan Corp Plc share of losses of Jansen Ai [Member]
Dec. 31, 2010
Elan Corp Plc share of losses of Jansen Ai [Member]
Sep. 16, 2011
Alkermes Plc [Member]
Mar. 31, 2012
Alkermes Plc [Member]
Mar. 13, 2012
Alkermes Plc [Member]
Sep. 16, 2011
Alkermes Plc [Member]
Dec. 31, 2012
Alkermes Plc [Member]
Dec. 31, 2011
Alkermes Plc [Member]
Dec. 31, 2012
Alkermes Plc [Member]
Discontinued Operations [Member]
Jan. 31, 2013
Alkermes Plc [Member]
Subsequent Event [Member]
Feb. 06, 2013
Alkermes Plc [Member]
Subsequent Event [Member]
Sep. 16, 2011
Alkermes Inc. [Member]
Schedule of Equity Method Investments [Line Items]                                                      
Elan ownership percentage     30.00%   49.90%             24.00%           25.00% 6.00%   25.00% 25.00%          
Funding commitment received with respect to collaboration $ 400.0       $ 500.0 $ 57.6         $ 500.0                                
Elan and Johnson & Johnson maximum additional commitment 400.0       76.9       29.9 400.0                                  
Unspent funding commitment           57.6                                          
Excess of losses over investment         11.0 0                                          
Asset impairment charge 117.3       678.9                                            
Claim on Janssen AI book value (after adjusting for basis differences)         0 117.3                                          
Difference between carrying amount and reported book value of net assets           185                               300          
Carrying value of equity method investment 14.0 675.8 209.0 235.0   130.6 209.0 235.0       20.0 14.0 17.3       528.6     528.6 528.6 527.9        
Amortization expense recorded related to basis differences         13.3 50.9 26.0                                        
Net loss in investment in associates (221.8) (81.1) (26.0)   (218.5) (78.4) (26.0)           (3.3) (2.7) (87.9)               7.2 0.7        
Initial funding commitment                   500.0                                  
Immaterial error from prior periods           27.5                                          
Purchase of equity method investment   20.0                   20.0                              
Ordinary shares                                   31.90 7.75   31.90           31.90
Share price                                   $ 16.57     $ 16.57           $ 16.57
Sale of ordinary shares                                     76.00%                
Ordinary shares                                     24.15 24.15   24.15     7.75    
Initial carrying value of available- for-sale investment                                           126.5   126.5      
Proceeds from sale of ordinary share $ 380.9                                   $ 380.9             $ 169.7